对心房动神经调节的发展:叙述性综述
Ning Yang1, Yang Zou1, Bohan Wen1
1Department of Cardiothoracic Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Journal of thoracic disease
|June 17, 2024
概括
自主神经系统 (ANS) 调制通过减少发作频率和严重程度,为心房动 (AF) 提供了有前途的治疗方法. 神经调节策略正在成为AF管理的有效,个性化的选择.
科学领域:
- 心脏病学 心脏病学
- 神经科学是一个神经科学.
- 医疗技术 医疗技术 医学技术
背景情况:
- 心房动 (AF) 是一种常见的心律失常,与显著的死亡率和残疾有关.
- 自主神经系统 (ANS) 通过结构和电气重塑,极大地影响着AF的发展和持续性.
- 传统的AF治疗面临挑战,引发了对自主干预策略的兴趣.
研究的目的:
- 审查关于AF治疗神经调节方法的临床前和临床研究.
- 确定对AF有前途的自主干预方法.
- 提供目前AF神经治疗方法的概述,突出优缺点.
主要方法:
- 从PubMed,WanFang数据和谷歌学者的文献进行叙事审查.
- 包括所有到2023年11月发表的相关研究.
主要成果:
- 心脏自主神经重塑是AF的一个关键因素.
- 神经调节方法,包括星状质 (SG) 切除,迷走神经刺激 (VNS) 和脏缩 (RDN),显示出潜在的潜力.
- 调节ANS活动可以显著降低AF发作频率和严重程度.
结论:
- 通过心脏自主神经重塑,ANS在AF病变发生过程中发挥着至关重要的作用.
- ANS调制为更有效和个性化的AF治疗提供了一条途径.
- 对AF的神经调节策略为改善患者结果提供了广泛的前景.
相关概念视频
Disturbances in Heart Rhythm
933
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
933
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
735
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
735
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
420
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
420
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
968
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
968


